Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
CCXI's Cash to Debt is ranked higher than
80% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CCXI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CCXI' s 10-Year Cash to Debt Range
Min: 6.43  Med: 262.19 Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 23.67
M-Score: -4.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -40.09
CCXI's ROE (%) is ranked lower than
58% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CCXI: -40.09 )
Ranked among companies with meaningful ROE (%) only.
CCXI' s 10-Year ROE (%) Range
Min: -42.81  Med: -30.25 Max: -4.02
Current: -40.09
-42.81
-4.02
ROA (%) -37.55
CCXI's ROA (%) is ranked lower than
61% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. CCXI: -37.55 )
Ranked among companies with meaningful ROA (%) only.
CCXI' s 10-Year ROA (%) Range
Min: -35.64  Med: -28.15 Max: -3.07
Current: -37.55
-35.64
-3.07
ROC (Joel Greenblatt) (%) -3883.38
CCXI's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. CCXI: -3883.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CCXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3598.39  Med: -2639.91 Max: -151.03
Current: -3883.38
-3598.39
-151.03
» CCXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CCXI Guru Trades in Q2 2014

Chuck Royce 70,000 sh (unchged)
Jim Simons 54,900 sh (-72.52%)
» More
Q3 2014

CCXI Guru Trades in Q3 2014

Jim Simons 68,300 sh (+24.41%)
Chuck Royce 70,000 sh (unchged)
» More
Q4 2014

CCXI Guru Trades in Q4 2014

Chuck Royce 70,000 sh (unchged)
Jim Simons 63,923 sh (-6.41%)
» More
Q1 2015

CCXI Guru Trades in Q1 2015

Jim Simons 81,700 sh (+27.81%)
Chuck Royce 70,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.53
CCXI's P/B is ranked higher than
61% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. CCXI: 3.53 )
Ranked among companies with meaningful P/B only.
CCXI' s 10-Year P/B Range
Min: 1.34  Med: 2.84 Max: 4.98
Current: 3.53
1.34
4.98
Current Ratio 9.82
CCXI's Current Ratio is ranked higher than
74% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CCXI: 9.82 )
Ranked among companies with meaningful Current Ratio only.
CCXI' s 10-Year Current Ratio Range
Min: 6.61  Med: 10.59 Max: 19.54
Current: 9.82
6.61
19.54
Quick Ratio 9.82
CCXI's Quick Ratio is ranked higher than
74% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CCXI: 9.82 )
Ranked among companies with meaningful Quick Ratio only.
CCXI' s 10-Year Quick Ratio Range
Min: 6.61  Med: 10.59 Max: 19.54
Current: 9.82
6.61
19.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.23
CCXI's Price/Net Cash is ranked higher than
69% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. CCXI: 5.23 )
Ranked among companies with meaningful Price/Net Cash only.
CCXI' s 10-Year Price/Net Cash Range
Min: 1.97  Med: 3.73 Max: 7.68
Current: 5.23
1.97
7.68
Price/Net Current Asset Value 5.13
CCXI's Price/Net Current Asset Value is ranked higher than
65% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. CCXI: 5.13 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CCXI' s 10-Year Price/Net Current Asset Value Range
Min: 1.95  Med: 3.69 Max: 7.47
Current: 5.13
1.95
7.47
Price/Tangible Book 3.51
CCXI's Price/Tangible Book is ranked higher than
68% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CCXI: 3.51 )
Ranked among companies with meaningful Price/Tangible Book only.
CCXI' s 10-Year Price/Tangible Book Range
Min: 1.56  Med: 2.83 Max: 4.92
Current: 3.51
1.56
4.92
Earnings Yield (Greenblatt) (%) -17.23
CCXI's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CCXI: -17.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CCXI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -23.1  Med: 0.00 Max: 0
Current: -17.23
-23.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2CX.Germany,
Chemocentryx Inc was incorporated in the state of Delaware on November 8, 1996. The Company is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development. CCX168 —Targeting the chemoattractant receptor known as C5aR, CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated renal vasculitis, or AARV. CCX140 — Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Vercirnon (also known as Traficet-EN, or CCX282) —Targeting the chemokine receptor known as CCR9, vercirnon is its drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. CCX872 — its second generation orally administered inhibitor targeting CCR2, CCX872 is expected to complete Phase I clinical development. CCX507 — its second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development. Its current drug candidates are manufactured using common chemical engineering and synthetic processes from readily available raw materials. It rely on contract manufacturing organizations to produce its drug candidates in accordance with the FDA's current good manufacturing practices, or cGMP, regulations for use in its clinical trials. The Company competes in the pharmaceutical, biotechnology and other related markets that address AARV, chronic kidney disease and diabetic nephropathy, IBD, rheumatoid arthritis, other autoimmune diseases and inflammatory disorders, and cancer. The Company competes with the pharmaceutical companies that currently sell or are developing drugs include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bayer, Bristol-Myers Squibb, Elan, Roche/Genentech, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Sanofi and Teva. The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
New ipo recommended Sep 16 2012 

More From Other Websites
Positive Results From ChemoCentryx Phase II Diabetic Nephropathy Trial With Chemokine Receptor CCR2... May 29 2015
Positive Clinical Data From ChemoCentryx Phase II Trial in Diabetic Nephropathy to be Presented at... May 26 2015
Positive Clinical Data From ChemoCentryx Phase II Trial in Diabetic Nephropathy to be Presented at... May 26 2015
CHEMOCENTRYX, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
ChemoCentryx upgraded by JP Morgan May 18 2015
CHEMOCENTRYX, INC. Financials May 15 2015
ChemoCentryx to Present at Two Upcoming Investor Conferences May 12 2015
ChemoCentryx to Present at Two Upcoming Investor Conferences May 12 2015
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report May 08 2015
ChemoCentryx Inc Earnings Call scheduled for 5:00 pm ET today May 06 2015
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2015
ChemoCentryx Reports First Quarter 2015 Financial Results and Provides Corporate Update May 06 2015
Q1 2015 ChemoCentryx Inc Earnings Release - After Market Close May 06 2015
ChemoCentryx to Hold First Quarter 2015 Financial Results Conference Call on Wednesday, May 6, 2015 Apr 22 2015
ChemoCentryx to Hold First Quarter 2015 Financial Results Conference Call on Wednesday, May 6, 2015 Apr 22 2015
ChemoCentryx Initiates Clinical Trial of CCX872, Its Next-Generation, Orally Administered CCR2... Apr 20 2015
ChemoCentryx Initiates Clinical Trial of CCX872, Its Next-Generation, Orally Administered CCR2... Apr 20 2015
Catalysts and Data Could Move 4 Top Biotech Stocks to Buy Apr 06 2015
CHEMOCENTRYX, INC. Files SEC form 10-K, Annual Report Mar 13 2015
ChemoCentryx's Q4 Loss Meet Estimates, Pipeline in Focus - Analyst Blog Mar 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK